KMT2A and acute lymphoblastic leukemia: Recent reports have indeed shown a supporting role for RUNX1 in leukemogenesis, primarily in AML, but also in T-ALL and mixed-lineage leukemia (MLL), offering a therapeutic rationale for targeting RUNX1 and its cofactor CBFβ16,17,22,23.